Results 1 to 10 of about 3,026 (154)

Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection [PDF]

BMC Infectious Diseases
Background Recurrent or refractory Clostridioides difficile infection (CDI) often affects older and immunocompromised patients, posing clinical and economic challenges.
Isabella Alram, Sebastian M. Wingen-Heimann, Marie Engelhard, Nele Pfeiffer, J. Janne Vehreschild, Maria J. G. T. Vehreschild, Sina M. Pütz   +6 more
doaj   +2 more sources

Improving fidaxomicin production through ARTP mutagenesis and fermentation optimization in Actinoplanes deccanensis [PDF]

Synthetic and Systems Biotechnology
Fidaxomicin, a macrolide antibiotic, is widely used to treat Clostridioides difficile infection (CDI). It demonstrats significantly higher clinical efficacy than vancomycin and metronidazole. However, the large-scale industrial production of it remains a
Jing-Yi Ruan, Huang Xie, Yi-Lei Zheng, Qing-Wei Zhao, Xin-Ai Chen, Zhong-Yuan Lyu, Yong-Quan Li   +6 more
doaj   +2 more sources

Antimicrobial Resistance of Clostridioides (Clostridium) difficile in Cambodia [PDF]

Antibiotics
Background/Objectives: Antimicrobial resistance (AMR) remains a major topic of interest in infectious disease management. We studied AMR in Clostridioides difficile isolated in Cambodia.
Lengsea Eng, Papanin Putsathit, Su-Chen Lim, Jessica M. Chisholm, Deirdre A. Collins, Archie C. A. Clements, Kefyalew Addis Alene, Thomas V. Riley   +7 more
doaj   +2 more sources

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection

Antibiotics, 2023
Fidaxomicin, a macrocyclic antibiotic, selectively kills Clostridioides difficile and reduces C. difficile infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective.
Laura Whitney, John Nesnas, Timothy Planche   +2 more
doaj   +1 more source

Transcriptional regulation of the fidaxomicin gene cluster and cellular development in Actinoplanes deccanensis YP-1 by the pleiotropic regulator MtrA

Microbiology Spectrum, 2023
Fidaxomicin is an 18-membered glycosidic macrolide polyketide that was clinically used in the treatment of Clostridium difficile infection in 2011. Although the biosynthetic mechanism and pathway-specific regulator of fidaxomicin were well elaborated ...
Huang Xie, Jing-Yi Ruan, Qing-Ting Bu, Yue-Ping Li, Yi-Ting Su, Qing-Wei Zhao, Yi-Ling Du, Yong-Quan Li   +7 more
doaj   +1 more source

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

Antibiotics, 2022
(1) Background: Fidaxomicin has been shown to significantly reduce Clostridioides difficile infection (CDI) recurrences rates in randomized, controlled trials.
Ronald G. Hall, Travis J. Cole, Chip Shaw, Carlos A. Alvarez   +3 more
doaj   +1 more source

A prospective, observational study of fidaxomicin use for infection in France

Journal of International Medical Research, 2021
Objective To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin.
Benoit Guery, Pierre Berger, Remy Gauzit, Magali Gourdon, Frédéric Barbut, , DAFNE study group:, Pascale Bémer, Emilie Bessède, Fabrice Camou, Vincent Cattoir, Carine Couzigou, Dominique Descamps, Aurélien Dinh, Caroline Laurans, Jean-Philippe Lavigne, Catherine Lechiche, Véronique Leflon-Guibout, Alban Le Monnier, Marion Levast, Joy Yoganaden Mootien, Yohan N’Guyen, Lionel Piroth, Thierry Prazuck, Olivier Rogeaux, Anne-Laure Roux, Anne Vachée, Véronique Vernet Garnier, Frédéric Wallet   +28 more
doaj   +1 more source

In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats

BMC Veterinary Research, 2023
Background Previous studies have demonstrated that fidaxomicin, a macrocyclic lactone antibiotic used to treat recurrent Clostridioides difficile-associated diarrhea, also displays potent in vitro bactericidal activity against Clostridium perfringens ...
Sergio Álvarez-Pérez, Blanca Anega, José L. Blanco, Marta Hernández, Marta E. García   +4 more
doaj   +1 more source

Fidaxomicin

RCSB Protein Data Bank
The Formulary Management Expert Committee (FMEC) recommends that fidaxomicin be reimbursed for the treatment of Clostridioides difficile infection (CDI) in adult patients who have an initial episode or first recurrence of CDI and are at high risk for recurrence or are allergic to vancomycin, provided certain conditions are met. Fidaxomicin should be
Steven Arnold, Helen Gao
  +6 more sources

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — An observational cohort study

International Journal of Infectious Diseases, 2021
Purpose: We aimed to evaluate the efficacy of different antibiotic regimens for the treatment of Clostridioides difficile infection (CDI) with regard to the CDI episode number and disease severity.
Sylvia Polivkova, Marcela Krutova, Vaclav Capek, Blanka Sykorova, Jiri Benes   +4 more
doaj   +1 more source